secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001437749-24-033614
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum reports Q3 2024 cash $213.9M, VISTA trial enrollment on track
-----------------------------------------------------------------------

- Cash, equivalents and marketable securities $213.9M as of Sept 30, 2024 (vs $125.2M at end of 2023).
- R&D expense $9.7M (+$3.2M YoY) driven by VISTA Phase 2 trial and PIPE-791 toxicology studies.
- VISTA trial for PIPE-307 in RRMS two-thirds enrolled; full enrollment expected first half 2025.
- Pending MHRA authorization, Phase 1b PET trial for PIPE-791 to start Dec 2024 with data in H1 2025.
- Janssen confirms on track to initiate Phase 2 trial of PIPE-307 in depression.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924033614/0001437749-24-033614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924033614/cont20241029_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-033614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer